Biliary Cholangitis
📧 Sign up to get email alerts when something new happens for Biliary Cholangitis.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2025-01-20EMA Revoked: Ocaliva (obeticholic acid) — Advanz Pharma Limited
EMA revoked the marketing authorization for Ocaliva (obeticholic acid) held by Advanz Pharma Limited, effective 16 April 2024, for biliary/l…
-
EMA withdrawal · 2024-06-28EMA recommends revoking conditional marketing authorisation for Ocaliva
EMA recommends revoking the conditional marketing authorisation for Ocaliva (obeticholic acid) after concluding that its benefits no longer …
-
CLINICAL_TRIALS withdrawal · 2012-10-08Clinical Trial Update: Stem Cell Transplantation in Patients With Primary Biliary Cirrhosis [Phase 1]
Phase 1 clinical trial of stem cell transplantation for primary biliary cholangitis has been withdrawn.